Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants

Vaccine

Volumn 31, Issue 41, 2013, Pages 4569-4577

  Melamed, Sharon ^a   Wyatt, Linda S ^a   Kastenmayer, Robin J ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Attenuated live vaccines; Recombinant vaccinia virus; Virus pathogenesis; Virus vectors

Indexed keywords

SMALLPOX VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HOST RANGE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VACCINE PRODUCTION; VACCINIA; VACCINIA VIRUS; VERO CELL;

ATTENUATED LIVE VACCINES; RECOMBINANT VACCINIA VIRUS; VIRUS PATHOGENESIS; VIRUS VECTORS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HOST SPECIFICITY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MUTATION; RECOMBINATION, GENETIC; SMALLPOX VACCINE; VACCINIA; VACCINIA VIRUS; VIRULENCE; VIRUS REPLICATION;

EID: 84883597395     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.057     Document Type: Article

References (44)

1. Hochstein-Mintzel V., Huber H.C., Stickl H. Virulenz und immunogenität eines modifizierten vaccinia-virus (Stamm MVA) [Virulence and immunogenicity of a modified vaccinia virus (strain MVA). Zeitschrift fur Immunitats-Forschung 1972, 144:140-145.
2. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schäfer H., Holzner A. MVA-stufenimpfung gegen pocken. klinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA (MVA vaccination against smallpox: clinical trials of an attenuated live vaccinia virus strain (MVA). Deutsche Medizinische Wochenschrift 1974, 99:2386-2392.
3. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA (Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA). Infection 1975, 3:6-14.
4. Mayr A., Stickl H., Müller H.K., Danner K., Singer H. Der pockenimpfstamm MVA: marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwächten organismus (The smallpox vaccination strain MVA: marker, genetic structure, experience gained with parenteral vaccination and behavior in organisms with debilitated defense mechanism. Zentralblatt Fur Bakteriologie Mikrobiologie Und Hygiene 1978, 167:375-390.
5. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10847-10851.
6. Sutter G., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12:1032-1040.
7. Drexler I., Staib C., Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential. Current Opinion in Biotechnology 2004, 15:506-512.
8. Gomez C.E., Najera J.L., Krupa M., Perdiguero B. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Current Gene Therapy 2011, 11:189-217.
9. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244:365-396.
10. Carroll M., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238:198-211.
11. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. Journal of General Virology 1998, 79:347-352.
12. Jordan I., Horn D., Oehmke S., Leendertz F.H., Sandig V. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Research 2009, 145:54-62.
13. Moss B. Poxviridae: the viruses and their replication. Fields Virology 2007, 2905-2946. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
14. Altenburger W., Süter C-P., Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Archives of Virology 1989, 105:15-27.
15. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Journal of General Virology 1991, 72:1031-1038.
16. Wyatt L.S., Carroll M.W., Czerny C-P., Merchlinsky M., Sisler J.R., Moss B. Marker rescue of the host range restricted defects of modified vaccinia virus Ankara. Virology 1998, 251:334-342.
17. Meisinger-Henschel C., Spath M., Lukassen S., Wolferstatter M., Kachelriess H., Baur K., et al. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. Journal of Virology 2010, 84:9907-9919.
18. Dimier J., Ferrier-Rembert A., Pradeau-Aubreton K., Hebben M., Spehner D., Favier A.L., et al. Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice. Journal of Virology 2011, 85:5016-5026.
19. Earl P.L., Moss B., Wyatt L.S., Carroll M.W. Generation of recombinant vaccinia viruses. Current Protocols in Molecular Biology 2001, Chapter 16:16/7/1-.7.9.
20. Earl P.L., Cooper N., Wyatt L.S., Moss B., Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. Current Protocols in Molecular Biology 2001, 4316:1-3.
21. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. Journal of General Virology 2007, 88:3249-3259.
22. Melamed S., Paran N., Katz L., Ben-Nathan D., Israely T., Schneider P., et al. Tail scarification with vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine 2007, 25:7743-7753.
23. Earl P.L., Cotter C., Moss B., Vancott T., Currier J., Eller L.A., et al. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009, 27:5885-5895.
24. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Montefiori D.C., Byrum R., et al. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 2007, 366:84-97.
25. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. International Journal of Infectious Diseases 2004, 8:S31-S44.
26. Okeke M.I., Nilssen O., Traavik T. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. Journal of General Virology 2006, 87:21-27.
27. Buller R.M.L., Smith G.L., Cremer K., Notkins A.L., Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985, 317:813-815.
28. Liu L.Z., Zhong Q., Tian T., Dubin K., Athale S.K., Kupper T.S. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nature Medicine 2010, 16:224-227.
29. Garcia-Arriaza J., Najera J.L., Gomez C.E., Tewabe N., Sorzano C.O.S., Calandra T., et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 2011, 6.
30. Falivene J., Zajac M.P.D., Pascutti M.F., Rodriguez A.M., Maeto C., Perdiguero B., et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 2012, 7.
31. Perdiguero B., Gomez C.E., Najera J.L., Sorzano C.O.S., Delaloye J., Gonzalez-Sanz R., et al. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS ONE 2012, 7.
32. Garber D.A., O'Mara L.A., Zhao J., Gangadhara S., An I., Feinberg M.B. Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS ONE 2009, 4.
33. Garber D.A., O'Mara L.A., Gangadhara S., McQuoid M., Zhang X., Zheng R., et al. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in Rhesus macaques. Journal of Virology 2012, 86:12605-12615.
34. Chavan R., Marfatia K.A., An I.C., Garber D.A., Feinberg A.B. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus Ankara enhances antiviral cellular and humoral immune responses. Journal of Virology 2006, 80:7676-7687.
35. Perera L.P., Waldmann T.A., Mosca J.D., Baldwin N., Berzofsky J.A., Oh S.K. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. Journal of Virology 2007, 81:8774-8783.
36. Jordan I., Vos A., Beilfuss S., Neubert A., Breul S., Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27:748-756.
37. Lohr V., Rath A., Genzel Y., Jordan I., Sandig V., Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: Studies on growth, metabolism and virus propagation. Vaccine 2009, 27:4975-4982.
38. Zwilling J., Sliva K., Schwantes A., Schnierle B., Sutter G. Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells. Virology 2010, 404:231-239.
39. Mayr A. Altered strain of the modified vaccinia virus Ankara (MVA). USA patent 6,682,743 B2; 2004.
40. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC - a highly attenuated strain of vaccinia virus. Virology 1992, 188:217-232.
41. Najera J.L., Gomez C.E., Domingo-Gil E., Gherardi M.M., Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. Journal of Virology 2006, 80:6033-6047.
42. Najera J.L., Gomez C.E., Garcia-Arriaza J., Sorzano C.O., Esteban M. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS ONE 2010, 5.
43. Quakkelaar E.D., Redeker A., Haddad E.K., Harari A., McCaughey S.M., Duhen T., et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS ONE 2011, 6:e16819.
44. Kibler K.V., Gomez C.E., Perdiguero B., Wong S.M., Huynh T., Holechek S., et al. Improved NYVAC-based baccine bectors. PLoS ONE 2011, 6.